Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric multiple sclerosis trial of fingolimod versus intramuscular interferon beta-1a with fingolimod extension
NL-OMON53151Phase 3Recruiting
- Sponsor
- Novartis
- Start
- Jan 2015
- Modality
- Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fingolimod and interferon beta-1a in multiple sclerosis (MS) (3 arms), sponsored by Novartis. Primary endpoints: Expanded Disability Status Scale, Magnetic resonance imaging and 1 more. Started Jan 2015; status: recruiting.
02
Drugs
fingolimodinterferon beta-1a
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NL-OMON53151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53151.